Travere Therapeutics Inc (TVTX)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 26 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
Uses AITravere Therapeutics ist ein Biopharma-Unternehmen für seltene Nierenerkrankungen (FILSPARI, Thiola) — KI ist keine Umsatzquelle. Der jüngste 10-K (GJ 2025) und der 10-Q Q1 2026 belegen aber ausdrücklich den operativen Einsatz: Mitarbeiter nutzen generative KI, Machine Learning und automatisierte Entscheidungssysteme für ihre Arbeit („Our employees and personnel use generative artificial intelligence …“), und das Unternehmen räumt ein, dass ein Verzicht auf KI das Geschäft ineffizienter machen und Wettbewerbsnachteile bringen würde. Die übrigen KI-Erwähnungen sind Datenschutz-/Cyber-Risikoklauseln rund um diese eigene Nutzung — kein konkretes Geschäftsmodell-Risiko, keine KI-Produkte.
View the full file — quotes, sources, reviewed filings
„Our employees and personnel use generative artificial intelligence, machine learning and other artificial intelligence technologies (together, “AI/ML”) and/or automated decision-making technologies to perform their work, and the disclosure and use of personal data in AI/ML technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiterinnen und Mitarbeiter nutzen generative künstliche Intelligenz, maschinelles Lernen und andere KI-Technologien (zusammen „AI/ML“) und/oder automatisierte Entscheidungstechnologien für ihre Arbeit; die Offenlegung und Verwendung personenbezogener Daten in AI/ML-Technologien unterliegt verschiedenen Datenschutzgesetzen und weiteren Datenschutzpflichten.
„If we are unable to use AI/ML and/or automated decision-making technologies in the future, it could make our business less efficient and result in competitive disadvantages."
Sollten wir AI/ML und/oder automatisierte Entscheidungstechnologien künftig nicht nutzen können, könnte das unser Geschäft ineffizienter machen und zu Wettbewerbsnachteilen führen.
„Any sensitive information (including confidential, competitive, proprietary, or personal data) that we input into a third-party generative AI/ML platform could be leaked or disclosed to others, including if sensitive information is used to train the third parties’ AI/ML model."
Sämtliche sensiblen Informationen (einschließlich vertraulicher, wettbewerbsrelevanter, geschützter oder personenbezogener Daten), die wir in eine generative AI/ML-Plattform eines Drittanbieters eingeben, könnten durchsickern oder an Dritte gelangen — etwa wenn sensible Informationen zum Training des AI/ML-Modells des Drittanbieters verwendet werden.
Filings Reviewed: 10-Q 2026-05-04 · 10-Q 2025-10-30 · 10-Q 2025-08-06 · 10-Q 2025-05-01 · 10-K 2026-02-19 · 10-K 2025-02-21
Rated on July 8, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.73 | – | 75 | 66.00 | -80.60 | -36 | -45 |
| 2025: Q1 | -0.47 | – | 82 | 97.50 | -50.40 | -42 | -54 |
| 2025: Q2 | -0.14 | – | 114 | 111.50 | -11.10 | 5 | 5 |
| 2025: Q3 | 0.25 | – | 165 | 162.10 | 15.60 | 14 | 14 |
| 2025: Q4 | 0.03 | – | 130 | 73.40 | 2.10 | 61 | 61 |
| 2026: Q1 | -0.40 | – | 127 | 55.60 | -29.20 | -40 | -63 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Travere Therapeutics, Inc., ein biopharmazeutisches Unternehmen, identifiziert, entwickelt und liefert Therapien für Menschen mit seltenen Nieren- und Stoffwechselerkrankungen in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 497 |
| Headquarters | San Diego, CA |
| Website | travere.com |
| IPO Date | 8. Nov 2012 |
| Next Earnings | 5. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Eric M. Dube Ph.D. | President, CEO & Director | 1973 |
| Christopher Cline C.F.A. | Chief Financial Officer | 1985 |
| William E. Rote Ph.D. | Chief Research Officer | 1963 |
| Peter Heerma | Chief Commercial Officer | 1971 |
| Jula Inrig M.D. | Chief Medical Officer | 1975 |
| Sandra Calvin | SVP, Corporate Controller & Chief Accounting Officer | 1966 |
| Nivi Nehra | Vice President of Corporate Communications & Investor Relations | – |
| Elizabeth E. Reed J.D. | Chief Legal Officer, General Counsel & Secretary | 1971 |
| Angela Giannantonio | Chief People Officer | – |
| Casey Logan | Chief Business Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.